alecensa
roche registration gmbh - alectinibhydroklorid - karsinom, ikke-småcellet lunge - antineoplastiske midler - alecensa som monoterapi er indisert for førstegangsbehandling av voksne pasienter med anaplastisk lymfomkinase (alk) -positive avansert ikke-småcellet lungekreft (nsclc). alecensa som monoterapi er indisert for behandling av voksne pasienter med alk‑positive avansert nsclc som tidligere er behandlet med crizotinib.
alfentanil hameln 0.5 mg/ ml
hameln pharma gmbh - alfentanilhydrokloridhydrat - injeksjonsvæske, oppløsning - 0.5 mg/ ml
iclusig 15 mg
abacus medicine a/s - ponatinibhydroklorid - tablett, filmdrasjert - 15 mg
alfentanil kalceks 0.5 mg/ ml
as kalceks - alfentanilhydroklorid - injeksjons-/infusjonsvæske, oppløsning - 0.5 mg/ ml
rapifen 0.5 mg/ ml
piramal critical care b.v. - alfentanilhydrokloridhydrat - injeksjonsvæske, oppløsning - 0.5 mg/ ml
iclusig 15 mg
orifarm as - ponatinibhydroklorid - tablett, filmdrasjert - 15 mg
iclusig
incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. se avsnitt 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.
nimbex 2 mg/ ml
aspen pharma trading limited - cisatrakuriumbesilat - injeksjonsvæske, oppløsning - 2 mg/ ml